CSIMarket Company Name, Ticker, Industry, else..
 
Sana Biotechnology Inc   (NASDAQ: SANA)
 
Price: $3.1050 $-0.10 -2.969%
Day's High: $3.200000047683716 Week Perf: -2.05 %
Day's Low: $ 3.10 30 Day Perf: -12.54 %
Volume (M): 266,421 52 Wk High: $ 6.55
Volume (M$): $ 0 52 Wk Avg: $3.79
Open: $3.20 52 Wk Low: $2.61



 Market Capitalization (Millions $) 918
 Shares Outstanding (Millions) 296
 Employees 142
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -212
 Cash Flow (TTM) (Millions $) 13
 Capital Exp. (TTM) (Millions $) 3

Business Description


Sana Biotechnology Inc is a biotechnology company that focuses on cell engineering to create and deliver transformative cures for patients suffering from various diseases. The company utilizes advancements in stem cell biology, gene editing technologies, and other cellular therapies to develop novel treatments. Sana Biotechnology aims to tackle complex and challenging diseases by engineering cells to repair, replace, and enhance the body's natural functions. Their goal is to provide patients with new, advanced therapies that have the potential to significantly improve their quality of life.


   Company Address: 188 East Blaine Street Seattle 98102 WA
   Company Phone Number: 701-7914   Stock Exchange / Ticker: NASDAQ SANA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
DNA        1.01% 
IMCR   -11%    
KRYS   -5.23%    
MRNA        1.96% 
NVAX   -9.42%    
STRO   -18.82%    
• View Complete Report
   



Announcement

Class Action Filed Against Sana Biotechnology Amid Notable Financial Losses

Published Sun, Apr 13 2025 3:22 AM UTC

NEW YORK, April 12, 2025 Pomerantz LLP has announced the filing of a class action lawsuit against Sana Biotechnology, Inc. (NASDAQ: SANA) and certain top executives amidst growing scrutiny surrounding the company’s financial performance. The case, filed in the United States District Court for the Western District of Washington and docketed under number 25cv00512, claims...
Announcement

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certai...

Published Mon, Apr 7 2025 12:30 PM UTC

The Stormy Waters of Biotechnology: Analyzing Sana Biotechnology’s Legal and Financial ChallengesIn recent months, the biotechnology sector has faced its fair share of turbulence, with Sana Biotechnology, Inc. (NASDAQ: SANA) emerging as a key player caught in the crosshairs of legal battles and increasing financial scrutiny. This article delves into a class action lawsuit...
Clinical Study

Heralding a New Era in Diabetes Treatment Immunosuppression-Free Islet Cell Transplantation,

Published Tue, Jan 7 2025 10:22 PM UTC

Transformative Progress in Type 1 Diabetes: The Promise of Immunosuppression-Free Islet Cell Transplantation In a groundbreaking advancement for the treatment of Type 1 diabetes, Sana Biotechnology recently announced positive clinical results from their innovative study on islet cell transplantation that circumvents the need for immunosuppression. This first-in-human study d...
Management Announcement

Sana Biotechnology’s High-Stakes Race: Fast-Tracks and Financial Challenges in Autoimmune Treatment Landscape,

Published Mon, Dec 2 2024 2:01 PM UTC

Sana Biotechnology s Bold Gambit: Fast Tracking into the Future of Autoimmune Treatments Amid Financial TurbulenceBy CSI Market In a move that could reshape the landscape of autoimmune disease treatment, Sana Biotechnology Inc. recently announced it has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for its investigational therapy SC...
Clinical Study

Harnessing Innovative Biotechnology for the Treatment of Autoimmune Diseases Sana Biotechnologys Strategic Focus on ...

Published Mon, Nov 4 2024 9:30 PM UTC

: Sana Biotechnology has embarked on an ambitious initiative to leverage groundbreaking therapeutic platforms to address type 1 diabetes and B-cell mediated autoimmune diseases. As clinical trials edge closer, this article delves into the details of Sana’s promising candidates, namely UP421, SC451, and SC291, while also exploring advances in the treatment of refractory B...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 5.94
PEG (TTM) -

Financial Strength Current
Quick Ratio 2.59
Working Capital Ratio 2.64
Leverage Ratio (MRQ) 1.79
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.78 $
Revenues (TTM) -
Cash Flow (TTM) 0.04 $
Cash 1.09 $
Book Value 0.52 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,491,704
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.